We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison Between Two Different Dosages of Remifentanil During Colonoscopy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01229527
First Posted: October 27, 2010
Last Update Posted: February 1, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Agostoni Massimo, Fondazione SanRaffaele del Monte Tabor
  Purpose

The purpose of this randomized double-blind trial is to define the correct dosage of Remifentanil during operative and diagnostic endoscopic procedures. In particular we want to analyze if the administration of Remifentanil by PCSA (Patient Controlled Sedation and Analgesia) is a good method during colonoscopy, evaluating pain control, discharge time and side effects.

90 patients undergoing colonoscopy will be enrolled.


Condition Intervention Phase
Colonoscopy Drug: Remifentanil Drug: Meperidine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Supportive Care
Official Title: Comparison Between Two Different Dosages of Remifentanil Administered by PCSA (Patient Controlled Sedation and Analgesia) and Meperidine During Colonoscopy: A Randomized Double-Blind Trial

Resource links provided by NLM:


Further study details as provided by Agostoni Massimo, Fondazione SanRaffaele del Monte Tabor:

Primary Outcome Measures:
  • Discharge Time, the Time to Reach a Modified Aldrete Score ≥18 [ Time Frame: > 0 minutes ]
    Ten key parameters (Activity, Respiration, Circulation, Consciousness, O2 Saturation, Dressing, Pain, Ambulation, Fasting-feeding, Urine Output)are included in the Modified Aldrete Score. The maximum and minimum score for each parameter is respectively 2 and 0. The maximum total score is 20 and patient can be discharged when the total score is ≥18.


Secondary Outcome Measures:
  • Patient's Satisfaction [ Time Frame: After the end of colonoscopy (when patients were completely awake) and 24 h after the procedure via telephone ]
    The degree of satisfaction about the quality of sedation was measured with VAS (Visual Analog Scale) where 0 means no satisfaction and 100 means maximum satisfaction.


Enrollment: 90
Study Start Date: April 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Remifentanil RS1 Drug: Remifentanil
Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
Experimental: Remifentanil RS2 Drug: Remifentanil
Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
Active Comparator: Meperidine Drug: Meperidine
Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult Patients
  • Diagnostic and Operative Colonoscopy
  • ASA Physical Status I-II

Exclusion Criteria:

  • Age < 18 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01229527


Locations
Italy
San Raffaele Hospital
Milan, Italy, 20132
Sponsors and Collaborators
Ospedale San Raffaele
  More Information

Responsible Party: Agostoni Massimo, Medical Doctor, Fondazione SanRaffaele del Monte Tabor
ClinicalTrials.gov Identifier: NCT01229527     History of Changes
Other Study ID Numbers: PCSA/Remi 2009
First Submitted: October 26, 2010
First Posted: October 27, 2010
Results First Submitted: September 19, 2011
Results First Posted: February 1, 2012
Last Update Posted: February 1, 2012
Last Verified: January 2012

Keywords provided by Agostoni Massimo, Fondazione SanRaffaele del Monte Tabor:
Colonoscopy
Remifentanil
Sedation

Additional relevant MeSH terms:
Remifentanil
Meperidine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Adjuvants, Anesthesia